Twin Health has raised $53 million in Series E funding to expand its AI-driven digital twin platform for metabolic care. The round, led by Denmark-based Maj Invest, brings the Silicon Valley company’s valuation close to $950 million.
Simultaneously, Twin Health disclosed results from a Cleveland Clinic-led randomized clinical trial, published in NEJM Catalyst, demonstrating that its AI-supported system—referred to as the “Twin Precision Treatment”—achieved meaningful diabetes reversal and weight loss outcomes without reliance on high-cost medications.
How It Works
The Whole-Body Digital Twin platform builds a real-time AI digital twin for each individual by capturing up to 3,000 data points daily across 174 health markers—including glucose, weight, blood pressure, sleep, and activity—with seamless integration via Bluetooth and mobile technologies. Machine learning algorithms then generate highly personalized recommendations, delivering actionable guidance to users through an app and a human support team.
Twin Health operates under a performance-based pricing model for employers and health plans—paying only when members achieve meaningful outcomes like A1C reduction, weight loss, or medication elimination. If such milestones aren’t met, the service incurs no cost.
The company notes strong client retention and engagement metrics—90%+ retention, under 1% voluntary churn, and high conversion rates—indicating robust scalability.
Trial Highlights
- Within the Twin Health group, 71% of participants achieved an HbA1c level below 6.5% while taking only metformin, compared to just 2.4% in the usual care group.
- 85% of participants eliminated GLP-1 therapy in the Twin Health arm.
- Participants using the intervention also saw pronounced weight loss: –8.6% versus –4.6% with standard care.
- As Dr. Kevin M. Pantalone (lead investigator) stated: “Our study demonstrated the AI-enabled system of sensors to understand each patient’s unique metabolic profile, and AI-enabled human care team coaching facilitated significant improvements in glycemic control, weight loss, and quality of life versus usual care, while allowing marked de-escalation of glucose-lowering medications.”
- Dr. Lisa Shah, MD, Chief Medical Officer of Twin Health, added: “The study demonstrates that AI-driven precision medicine is the key to metabolic healing.”
Technology and Strategy
According to pharmaphorum, Twin Health’s platform “provides a model of a patient’s unique metabolism and can help people manage diabetes and weight loss.” The trial involved 150 primary care patients randomized into Twin Health vs. usual care groups.
As the company stated, the platform is helping employers and health plans “meet growing demand for responsible GLP-1 strategies” and reduce healthcare costs.
Funding Details and Market Implications
The new investment will support Twin Health’s expansion among health plans and corporate clients. Maj Invest’s CEO, Jeppe Christianson, emphasized the strategic significance: “Twin Health represents a paradigm shift in diabetes and obesity care—one that is precise to each individual and scalable for employers and health plans.”
